Navigation Links
NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
Date:11/12/2007

this study demonstrated its differences from previous attempts by the medical community to use radiation for the treatment of wet AMD. Additional on-going studies may well confirm the viability of this new therapeutic option for the elderly with wet AMD."

Unlike previous forms of radiation therapy for Wet AMD, NeoVista's approach delivers the peak dose of radiation directly to the lesion without damaging the underlying choroidal vasculature. Utilizing strontium-90, the focused radiation is delivered to a target area 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is comparable to 15 minutes of exposure to the sun.

"The ultimate promise of this therapy revolves around that fact that NeoVista's targeted radiation delivery system allows patients to continue living their lives, with significantly less injections, while also having the potential to save both patients and the healthcare system billions of dollars," said John N. Hendrick, President and CEO of NeoVista. "We look forward to unveiling the true impact of our therapy on patients and physicians now that our larger CABERNET trial is underway."

The CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial is a multi-center, randomized, controlled study which will enroll 450 subjects at 30 sites worldwide (20 in the United States). The study will evaluate the safety and efficacy of NeoVista's beta radiation epiretinal therapy delivered concomitantly with the FDA approved antiangiogenic therapy, Lucentis(R), versus Lucentis(R) alone.

About NeoVista, Inc.

NeoVista, Inc. is a privately held development-stage medical device company based in Fremont, California. NeoVista's beta radiation epiretinal therapy is currently being studied in a definitive clinical study to support eventual filing for regulatory approval to market
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...Pharmaceuticals (SPI) has filed,an Investigational...l,testing of a proprietary formulation of ebselen ... loss or ototoxicity. The oral capsule,containing ...e lung cancer,and head and neck cancer patients re...e second development program for SPI to enter clin...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/23/2008)...th Protein Therapeutics that Modulate Al..., Mass., July 23 /- Taligen Therapeut...ate growth plan with the,appointment of Abbie Celn...tablishment of its headquarters in Cambridge, Mass...-founder of the company who remains president., U...
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 1Symmetry Medical Delays 10 K Filing to Complete Review 15357 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 3Symmetry Medical Delays 10 K Filing to Complete Review 15357 4Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 1Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 2Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 3Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 1Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 2Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 3Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 1Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 2
...Annual Meeting of the American,Psychiatric Associa...all/ -- In adults with,major depressive disorder, ...) resulted in significant improvement in the prima...ing Scale (MADRS),Total Score. In this six-week, r... at the 160th Annual Meeting of the American,Psych...
...ewswire/ -- Asenapine -- an,investigational drug b...siness unit of Akzo Nobel, for bipolar I disorder ...ffective than placebo,in treating acute manic and ... according to new Phase III results, from a study,...s 2007 Annual,Meeting. , In the three-week study, ...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4
(Date:7/25/2008)...er Releases Results of Fourth Annual Physician On-...DETROIT, July 25 /PRNewswire/ -- Sullivan, Cotter ...al survey of physician on-call pay rates and,pract.... The survey report,with data from 132 healthcare...all pay practices and rates paid for 33 physician ...
(Date:7/25/2008)...ionship Based on Significant Improvements in Membe...tacor, Inc., a leader in health,care quality manag...day,announced it has entered into a long-term agre...ellmark,s Collaboration on Quality(SM) Incent and,...between Wellmark and,primary care clinicians to pr...
(Date:7/25/2008)...ly 25 /PRNewswire/ -- The Elekta Family of Compani...ment solutions at the 2008,American Association of...onstrating how the joint forces of Elekta, IMPAC a...py planning and delivery solutions that,streamline...ce for,patients, as well as enhance clinician effi...
(Date:7/25/2008)...id back-up in esophagus can cause immune system ch...s) -- The first evidence linking gastroesophageal ...ed by Duke University Medical Center researchers. ... first noted in the 1970s, and since then studies ...of asthma patients also experience GERD symptoms. ...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2
...g rod of Chikungunya, the ruling Left Democratic... quest for a 'politically correct' low-cost health...Front (LDF) government had dumped its BPL (below p...CI Lombard to seek out a cost-competitive, quality...
... lymphoma became substantially more common in the ... a report in the July issue of Archives of Dermato...nd geographic area. Cutaneous T-cell lymphoma occ...tem (called T lymphocytes) become cancerous and af...
...t his 90 day stint at the Betty Ford clinic in Pal...to Nicole Kidman from collapsing . The singer ent... after the couple wed in June that year. Urban ho...tering rehab at the time was one of the wisest dec...
...ssage in one ear while a friend is talking into yo... an important communication skill thats heavily in...ional Institute on Deafness and Other Communicatio...l Institutes of Health. The finding, published in...
Other Medicine News:Health News:Kerala Government Battles With Chikungunya On All Counts 2Health News:Cutaneous T-cell Lymphoma Shows Steady Increase 2Health News:Genes Influence the Ability to Listen Two Things at a Time 2Health News:Genes Influence the Ability to Listen Two Things at a Time 3
The Sphincter of Oddi Manometry Application for POLYGRAM NET™ (PNET) works with the Polygraf™ ID multiparametric recorder to record and analyze pressure signals from sphincter of Oddi man
...rise the SmartPill GI Monitoring System., ,Three ...toring System: SmartPill pH.p Capsule software, Sm...iGI software. These three components are integrate...toring System and function together with system ha...
... NET™ (PNET) works with the Polygraf™ ...pressure signals from continuous pull-through proc...cter (LES)., ,Continuous pull-through procedures ...r Puller, but they may be carried out manually wit...
... POLYGRAM NET™ works with the Polygraf&trade...e multichannel EGG signals. The EGG analysis takes...ng an automatic electrode impedance check on every...ording. If the electrode impedance is measured abo...
Medicine Products: